BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20513085)

  • 1. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
    Capria S; Gentile G; Capobianchi A; Cardarelli L; Gianfelici V; Trisolini SM; Foà R; Martino P; Meloni G
    J Med Virol; 2010 Jul; 82(7):1201-7. PubMed ID: 20513085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of cytomegalovirus (CMV)-pp65 antigenemia in the diagnosis of CMV disease in human immunodeficiency virus-infected patients.
    Reynes J; Montes B; Atoui N; Segondy M
    J Med Virol; 1996 Jul; 49(3):195-8. PubMed ID: 8818964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment.
    Allice T; Cerutti F; Pittaluga F; Varetto S; Franchello A; Salizzoni M; Ghisetti V
    J Virol Methods; 2008 Mar; 148(1-2):9-16. PubMed ID: 18045702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis value of the pp65 antigenemia and semi-quantitative PCR in the detection of the CMV reactivation in bone marrow grafted patients].
    Ksouri H; Lakhal A; Ben Amor R; Torjman L; Achour W; Ben Othmen T; Ladeb S; Abdelkefi A; Slim A; Abdeladhim A; Ben Hassen A
    Bull Soc Pathol Exot; 2006 Jul; 99(3):155-9. PubMed ID: 16983816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H; Müller C; Löffler J; Jahn G; Einsele H
    Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytomegaloviral infection in patients with hemoblastoses].
    Savchenko VG; Troitskaia VV; Misiurin AV; Parovichnikova VN; Isaev VG; Mendeleeva LP; Liubimova LS; Demidova IA; Aksenova EV; Filatov FP
    Ter Arkh; 2003; 75(7):52-8. PubMed ID: 12934482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring low cytomegalovirus viremia in transplanted patients by a real-time PCR on plasma.
    Schvoerer E; Henriot S; Zachary P; Freitag R; Fuchs A; Fritsch S; Risch S; Meyer N; Caillard S; Lioure B; Stoll-Keller F
    J Med Virol; 2005 May; 76(1):76-81. PubMed ID: 15778970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
    Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
    Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy.
    D'Ovidio V; Vernia P; Gentile G; Capobianchi A; Marcheggiano A; Viscido A; Martino P; Caprilli R
    J Clin Virol; 2008 Oct; 43(2):180-3. PubMed ID: 18614396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.